<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752686</url>
  </required_header>
  <id_info>
    <org_study_id>Severance_BR_01</org_study_id>
    <secondary_id>DA-TNBC</secondary_id>
    <nct_id>NCT01752686</nct_id>
  </id_info>
  <brief_title>A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer</brief_title>
  <official_title>A Phase III Trial of Carboplatin as Adjuvant Chemotherapy Versus Observation in Triple Negative Breast Cancer With Pathologic Residual Cancer After Neoadjuvant Chemotherapy: POST-Neo Adjuvant Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the efficacy of carboplatin, as a post-operative&#xD;
      adjuvant chemotherapy for triple negative breast cancer patients who have pathologic residual&#xD;
      cancer after the preoperative chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Neo-adjuvant period Four cycles of 60 mg/m2 doxorubicin and 600 mg/m2 cyclophosphamide&#xD;
      therapy at 3-week intervals followed by four cycles of 100 mg/m2 docetaxel at 3-week&#xD;
      intervals.&#xD;
&#xD;
      In POST Neo-adjuvant period&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      At the time of post neo-adjuvant period, the patients will be assigned to each treatment&#xD;
      group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of&#xD;
      carboplatin (AUC=6) on the first day of every 21 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To compare DFS between carboplatin and observation within non-pCR (complete remission) patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 5years</time_frame>
    <description>To compare overall survival (OS) between carboplatin and observation within non-pCR patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR rate</measure>
    <time_frame>up to 3 years</time_frame>
    <description>To assess the pCR rate (no residual invasive carcinoma in primary breast and axillary lymph node) within total TNBC patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who receive breast conserving surgery.</measure>
    <time_frame>up to 3years</time_frame>
    <description>To assess the percentage of patients who receive breast conserving surgery within total triple negative breast cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>up to 3years</time_frame>
    <description>Number of adverse events in patients with non-pCR.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>difference in gene expression pattern</measure>
    <time_frame>up to 5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">587</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>carboplatin chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this observation arm, patients should be follow up with regular interval without treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin as adjuvant chemotherapy</description>
    <arm_group_label>carboplatin chemotherapy</arm_group_label>
    <other_name>Adding adjuvant arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of breast cancer&#xD;
&#xD;
               1. Female patients&#xD;
&#xD;
               2. Histologically confirmed invasive breast cancer&#xD;
&#xD;
                    1. Primary tumor greater than 2cm diameter, measured by mammography and&#xD;
                       sonography&#xD;
&#xD;
                    2. Any N&#xD;
&#xD;
               3. ER (estrogen receptor)/ PR (progesterone receptor) / HER2 (negative/ negative/&#xD;
                  negative)(ER &lt;1%, PR&lt;1%, IHC 0, 1+ or FISH - in case of IHC&#xD;
                  (immuno-histochemistry) 2+)&#xD;
&#xD;
               4. No evidence of metastasis (M0)&#xD;
&#xD;
               5. No prior hormonal, chemotherapy or radiotherapy is allowed.&#xD;
&#xD;
               6. No breast operation other than biopsy to make diagnosis is allowed.&#xD;
&#xD;
               7. Age: 20-years and older, not pregnant pre-, and postmenopausal women with good&#xD;
                  performance status (ECOG 0-1)&#xD;
&#xD;
               8. Adequate hematopoietic function: Absolute granulocyte count 1500/mm3, platelet&#xD;
                  100,000/mm3, Hemoglobin 10 g/mm3&#xD;
&#xD;
               9. Adequate renal function: Serum creatinine 1.5 mg/dl&#xD;
&#xD;
              10. Adequate hepatic function: total bilirubin: 1.5 mg/dl, AST(aspartate&#xD;
                  aminotransferase)/ALT (alanine transaminase): 2 times normal, Alkaline&#xD;
                  phosphatase:2 times normal&#xD;
&#xD;
              11. Written informed consent&#xD;
&#xD;
              12. Normal mental function to understand and sign the consent&#xD;
&#xD;
              13. Cardiac function: normal or nonspecific EKG taken within 1 mo of enrollment.&#xD;
&#xD;
              14. LVEF (left ventricular ejection fraction)50% by MUGA (multiple gated acquisition&#xD;
                  scan) or Echocardiogram taken within 1 mo of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received hormonal, chemotherapy or radiotherapy for breast cancer&#xD;
&#xD;
          2. Patients who underwent surgery for breast cancer&#xD;
&#xD;
          3. Patients with a history of uncompensated congestive heart failure&#xD;
&#xD;
          4. Patients with inflammatory breast cancer (T4d)&#xD;
&#xD;
          5. Patients without primary tumor (T0)&#xD;
&#xD;
          6. Patients who have history of cancer other than in situ uterine cervix cancer or&#xD;
             non-melanotic skin cancer&#xD;
&#xD;
          7. Known hypersensitivity to any of the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byeong Woo Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byeong Woo Park, MD, PhD</last_name>
    <phone>82-2-2228-8125</phone>
    <email>nobelg@yuhs.ac</email>
  </overall_contact>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Severance Hospital</investigator_affiliation>
    <investigator_full_name>Byeong Woo Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

